JP2016501538A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501538A5
JP2016501538A5 JP2015548131A JP2015548131A JP2016501538A5 JP 2016501538 A5 JP2016501538 A5 JP 2016501538A5 JP 2015548131 A JP2015548131 A JP 2015548131A JP 2015548131 A JP2015548131 A JP 2015548131A JP 2016501538 A5 JP2016501538 A5 JP 2016501538A5
Authority
JP
Japan
Prior art keywords
rna
therapeutic composition
rhabdovirus
cross
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501538A (ja
JP6612619B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/051009 external-priority patent/WO2014094182A1/en
Publication of JP2016501538A publication Critical patent/JP2016501538A/ja
Publication of JP2016501538A5 publication Critical patent/JP2016501538A5/ja
Application granted granted Critical
Publication of JP6612619B2 publication Critical patent/JP6612619B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548131A 2012-12-21 2013-12-20 非複製型ウイルス由来粒子及びその使用 Expired - Fee Related JP6612619B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261740856P 2012-12-21 2012-12-21
US61/740,856 2012-12-21
US201361835310P 2013-06-14 2013-06-14
US61/835,310 2013-06-14
PCT/CA2013/051009 WO2014094182A1 (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019165067A Division JP2020014467A (ja) 2012-12-21 2019-09-11 非複製型ウイルス由来粒子及びその使用

Publications (3)

Publication Number Publication Date
JP2016501538A JP2016501538A (ja) 2016-01-21
JP2016501538A5 true JP2016501538A5 (https=) 2017-02-02
JP6612619B2 JP6612619B2 (ja) 2019-11-27

Family

ID=50977496

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015548131A Expired - Fee Related JP6612619B2 (ja) 2012-12-21 2013-12-20 非複製型ウイルス由来粒子及びその使用
JP2019165067A Pending JP2020014467A (ja) 2012-12-21 2019-09-11 非複製型ウイルス由来粒子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019165067A Pending JP2020014467A (ja) 2012-12-21 2019-09-11 非複製型ウイルス由来粒子及びその使用

Country Status (17)

Country Link
US (2) US11110138B2 (https=)
EP (1) EP2935569B1 (https=)
JP (2) JP6612619B2 (https=)
KR (1) KR102167497B1 (https=)
CN (1) CN105121636A (https=)
AU (1) AU2013362761B2 (https=)
BR (1) BR112015015045A8 (https=)
CA (1) CA2896162C (https=)
CL (1) CL2015001738A1 (https=)
ES (1) ES2745599T3 (https=)
IL (1) IL239486B (https=)
MX (1) MX376266B (https=)
MY (1) MY174912A (https=)
PH (1) PH12015501442A1 (https=)
RU (1) RU2705556C2 (https=)
SG (2) SG11201504843UA (https=)
WO (1) WO2014094182A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014094182A1 (en) * 2012-12-21 2014-06-26 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN109985244A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109432098B (zh) * 2018-11-20 2021-04-13 天津大学 化合物ps-341在制备小rna病毒科肠道病毒属病毒抑制剂的应用
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
HK1052950B (en) * 2000-06-26 2005-06-24 Wellstat Biologics Corporation Purging of cells using viruses
JP2005537802A (ja) 2002-09-09 2005-12-15 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション ラブドウイルスの組み換え型変異体及びその使用方法
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
AU2003279770A1 (en) 2002-10-01 2004-04-23 Novartis Vaccines And Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
DE602004018284D1 (de) 2003-03-27 2009-01-22 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US7807176B2 (en) * 2004-03-19 2010-10-05 Genomidea, Inc. Polypeptide promoting vascular endothelial cell growth
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
JP5547640B2 (ja) * 2008-09-16 2014-07-16 ジェノミディア株式会社 前立腺癌の治療・予防剤
CA2836117C (en) * 2009-12-10 2017-08-15 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US20130302368A1 (en) * 2011-01-27 2013-11-14 Boro Dropulic Advanced Prime and Boost Vaccine
CN103403594B (zh) * 2011-02-02 2016-11-23 康宁光缆系统有限责任公司 适用于为设备机架中的光学底板建立光学连接的稠密的光阀遮蔽的光纤连接器及总成
WO2012122649A1 (en) * 2011-03-15 2012-09-20 Ottawa Hospital Research Institute Recombinant orf virus
US9623096B2 (en) * 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof
WO2014094182A1 (en) * 2012-12-21 2014-06-26 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof

Similar Documents

Publication Publication Date Title
JP2016501538A5 (https=)
Choi et al. Polymeric oncolytic adenovirus for cancer gene therapy
Naik et al. Curative one-shot systemic virotherapy in murine myeloma
Chiocca et al. Oncolytic viruses and their application to cancer immunotherapy
Han et al. Combination of Metal‐Phenolic Network‐Based Immunoactive Nanoparticles and Bipolar Irreversible Electroporation for Effective Cancer Immunotherapy
Pol et al. Trial watch: oncolytic viruses for cancer therapy
Liu et al. Subunit nanovaccine with potent cellular and mucosal immunity for COVID-19
Di Gioia et al. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier
JP2019507761A5 (https=)
JP2018509888A5 (https=)
JP2013533747A5 (https=)
Zhu et al. Development and application of oncolytic viruses as the nemesis of tumor cells
JP2018502120A5 (https=)
JP2018530624A5 (https=)
EP3492597A3 (en) Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
JP2011519869A5 (https=)
JP2019523648A5 (https=)
JP2017538680A5 (https=)
JP2020533411A5 (https=)
JP2019508045A5 (https=)
JP2016501013A5 (https=)
JP2015524422A5 (https=)
RU2015128766A (ru) Нереплицируемые происходящие от вирусов частицы и их применение
JP2018023397A5 (https=)
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.